Business UpdateMay 19, 2026, 07:37 AM
Definium Therapeutics Posts Updated Corporate Presentation
AI Summary
Definium Therapeutics, Inc. announced it posted an updated corporate presentation on its website, detailing its late-stage pipeline, financial position, and anticipated milestones. The presentation highlights the DT120 ODT program in five Phase 3 studies with three key readouts expected in 2026 for Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD). The company reported a strong financial position with $373.4 million in cash, cash equivalents, and investments as of March 31, 2026, projecting a cash runway into 2028.
Key Highlights
- Definium Therapeutics posted an updated corporate presentation on May 19, 2026.
- DT120 ODT is the lead clinical program with five Phase 3 studies.
- Three Phase 3 readouts for GAD and MDD are anticipated in 2026.
- Cash, cash equivalents, and investments totaled $373.4 million as of March 31, 2026.
- Cash runway is expected to extend into 2028 based on current operating plan.
- DT402 Phase 2a study in ASD is underway, with initial data expected in 2026.
- Q1 2026 operating expenses were $59.2 million, including $41.5 million in R&D.
- Topline readouts: Emerge (MDD) late 2Q 2026, Voyage (GAD) early 3Q 2026, Panorama (GAD) late 3Q 2026.
Price Impact
More from DFTX